MorphoSys to acquire Constellation Pharmaceuticals for $1.7 billion
MLex Summary: Munich, Germany-based MorphoSys said it will acquire Cambridge, Massachusetts-based Constellation Pharmaceuticals for $1.7 billion. The combination gives Constellation, a clinical-stage biopharmaceutical company involved in cancer products, with Constellation, whose two lead...To view the full article, register now.
Already a subscriber? Click here to view full article